Heterocyclic PGI2 Agonists for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, including salazosulfapyridine, 5-aminosalicylic acid, steroids, and immunosuppressants, fail to achieve sufficient therapeutic effects and are associated with significant side effects, particularly with long-term administration.
Innovation Solution
The use of heterocyclic compounds like 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (compound A) or its pharmaceutically acceptable salt, which has shown therapeutic efficacy in rat models of colitis, administered in various pharmaceutical forms including oral and parenteral preparations, to treat inflammatory bowel diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids or immunosuppressants are used for treatment, then anti-inflammatory effect is improved, but side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of known PGI2 receptor agonists to create new compounds with improved therapeutic profiles. Specifically, the invention develops compounds with the general formula (1) that maintain anti-inflammatory efficacy while reducing side effects through structural optimization, including modifications to the substituent groups R1-R6 on the pyrazine ring system.
Solution Approach 2:
The patent employs composite materials by combining multiple functional groups within a single molecular structure. The compounds contain a pyrazine core with various substituent patterns that work synergistically to provide both anti-inflammatory activity and reduced toxicity, effectively creating a multi-functional therapeutic agent that addresses multiple aspects of the disease while minimizing harmful effects.
2Duration of action of stationary object
If conventional drugs are administered long-term, then therapeutic effect is maintained, but side effects accumulate
Solution Approach 1:
The patent applies self-service by designing compounds that inherently possess reduced side effect profiles through their molecular structure, eliminating the need for external intervention or monitoring to mitigate toxicity. The structural features of compounds (1) inherently provide selective action on inflammatory pathways while sparing normal physiological functions, allowing long-term use without cumulative toxicity.
3Adaptability or versatility
If existing therapeutic agents are used, then treatment coverage is provided, but sufficient therapeutic effect is not achieved
Solution Approach 1:
The patent applies universality by creating compounds that can effectively treat multiple types of inflammatory bowel diseases including ulcerative colitis and Crohn's disease through a single mechanism of action. The PGI2 receptor agonist activity of compounds (1) provides broad-spectrum anti-inflammatory coverage across different disease manifestations while maintaining consistent therapeutic efficacy.
Data Source
Figure 1~2
AI summary
The main object of the present invention is to provide an agent for the treatment of inflammatory bowel diseases. The present invention relates to an agent for the treatment of inflammatory bowel diseases containing the heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient; In the formula (1), and are the same or different and each represents an optionally substituted aryl; R3 and R4 are the same or different and each represents hydrogen atom or alkyl; R5 represents hydrogen atom, alkyl or halogen atom; Y represents N or N→O; A represents NR6, and R6 represents hydrogen atom, alkyl, etc.; D represents alkylene or alkenylene which is optionally substituted with hydroxy; E represents phenylene or a single bond; G represents O, S, etc.; and Q represents carboxy, alkoxycarbonyl, etc.